Stocklytics Platform
Asset logo for symbol STTK
Shattuck Labs
STTK49
$1.37arrow_drop_down10.21%-$0.14
Penny Stock
Asset logo for symbol STTK
STTK49

$1.37

arrow_drop_down10.21%

Performance History

Chart placeholder
Key Stats
Open$1.25
Prev. Close$1.22
EPS-1.85
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$66.81M
PE Ratio-
LOWHIGH
Day Range1.15
1.54
52 Week Range1.12
11.76
Ratios
EPS-1.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Shattuck Labs (STTK)

Shattuck Labs Inc (STTK) is a biotechnology company that specializes in the development of immuno-oncology therapies. The company's stock price history has shown volatility in recent years, with fluctuations in response to market conditions and company-specific news. Investors should carefully consider their risk tolerance before investing in STTK.
Recently, there has been positive news surrounding Shattuck Labs Inc. The company announced promising results from its Phase 1 clinical trial for its lead product candidate, which showed encouraging efficacy and safety data. These positive results have generated excitement among investors and analysts, driving up the stock price.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Taylor H. Schreiber M.D., Ph.D.
Headquarters
Austin
Employees
105
Exchange
NASDAQ
add Shattuck Labs to watchlist

Keep an eye on Shattuck Labs

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Shattuck Labs 's (STTK) price per share?

The current price per share for Shattuck Labs (STTK) is $1.37. The stock has seen a price change of -$0.14 recently, indicating a -10.22% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Shattuck Labs (STTK)?

For Shattuck Labs (STTK), the 52-week high is $11.76, which is 758.39% from the current price. The 52-week low is $1.12, the current price is 22.32% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Shattuck Labs (STTK) a growth stock?

Shattuck Labs (STTK) has shown an average price growth of -4.94% over the past three years. It has received a score of 8 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Shattuck Labs as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Shattuck Labs (STTK) stock price performance year to date (YTD)?

As of the latest data, Shattuck Labs (STTK) has a year-to-date price change of -81.88%. Over the past month, the stock has experienced a price change of -12.18%. Over the last three months, the change has been -56.09%. Over the past six months, the figure is -83.84%.
help

Is Shattuck Labs (STTK) a profitable company?

Shattuck Labs (STTK) has a net income of -$87.3M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.43K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.66M, although specific revenue growth data is currently not available. Operating income is noted at -$91.96M. Furthermore, the EBITDA is -$86.32M.
help

What is the market capitalization of Shattuck Labs (STTK)?

Shattuck Labs (STTK) has a market capitalization of $65.39M. The average daily trading volume is 1.34, indicating the stock's liquidity and investor engagement.

News

STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm
SHATTUCK LABS
SL-172154
MYELOID LEUKEMIA
MYELODYSPLASTIC SYNDROMES
Oct 27, 2024

STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
PRESS RELEASES
CONTESTS/AWARDS
Jul 1, 2024

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Wall Street Breakfast: The Week Ahead
Jun 30, 2024

Wall Street Breakfast: The Week Ahead

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Jun 14, 2024

Shattuck (STTK) Announces Positive Interim Data on Cancer Drug

Assessing Shattuck Labs: Insights From 6 Financial Analysts
ANALYST RATINGS
Jun 14, 2024

Assessing Shattuck Labs: Insights From 6 Financial Analysts

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
CLINICAL STUDY
Jun 14, 2024

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level